Loading stock data…
Schrödinger (SDGR)
$17.39+0.53 (+3.14%)
After Hours$17.43+0.04 (+0.23%)· Last close Jun 29
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Schrödinger, Inc. in the Healthcare sector is trading at $17.39 with a market capitalization of $1.1B. Wall Street consensus targets $20.88 (8 analysts), implying a +20.0% move over the next 12 months. The stock is currently 27% below its 52-week high of $23.75, remaining 10.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $58.59M↓ | $87.23M↑ | $54.32M↓ | $54.76M↓ | $59.55M |
| Gross Profit | $29.55M↓ | $57.29M↑ | $28.04M↑ | $26.16M↓ | $31.12M |
| Operating Income | -$48.79M↓ | -$17.16M↑ | -$45.95M↑ | -$52.90M↓ | -$50.89M |
| Net Income | -$60.03M↓ | $32.51M↑ | -$32.80M↑ | -$43.17M↑ | -$59.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Af...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.00%
Volume
Today's trading volume
1.95M
Recent News
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks. On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an “Equal Weight” rating on the shares. Separately, Schrödinger, Inc. (NASDAQ:SDGR) maintained full-year guidance for ACV of $218 million to $228 million. The corporation expects 10% to […]
What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?
Schrodinger Inc (NASDAQ:SDGR) is one of the best long-term stocks to invest in according to Bill & Melinda Gates Foundation Trust. The stock is backed by 31 hedge funds. Schrodinger shares are up around 13% over the past month, and analysts see more upside in the stock. On June 9, Schrodinger Inc (NASDAQ:SDGR) announced it […]
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets
Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing it in line with the updated implied price target in the model. This mirrors recent Street research, where several firms have also cut price targets while stressing that the shift reflects refreshed views on valuation, revenue recognition and execution risks rather than a single catalyst. As you read on, you will see how these moving targets shape the evolving analyst narrative and what to watch...